Figure 1
From: Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer
Progression-free survival time of 36 patients with metastatic colorectal cancer who received sequential therapy with irinotecan and S-1 in the phase II study. The median progression-free survival was 7.7 months (95% confidence interval, 4.8–12.6 months).
